Hydrogen peroxide is a component of cigarette smoke known to be essential for inactivation of ␣ 1 -antitrypsin, the primary inhibitor of neutrophil elastase. To establish the molecular basis of the inactivation of ␣ 1 -antitrypsin, we determined the sites oxidized by hydrogen peroxide. Two of the nine methionines were particularly susceptible to oxidation. One was methionine 358, whose oxidation was known to cause loss of antielastase activity. The other, methionine 351, was as susceptible to oxidation as methionine 358. Its oxidation also resulted in loss of anti-elastase activity, an effect not previously recognized. The equal susceptibility of methionine 358 and methionine 351 to oxidation was confirmed by mass spectrometry. To verify this finding, we produced recombinant ␣ 1 -antitrypsins in which one or both of the susceptible methionines were mutated to valine. M351V and M358V were not as rapidly inactivated as wild-type ␣1-antitrypsin, but only the double mutant M351V/M358V was markedly resistant to oxidative inactivation. We suggest that inactivation of ␣ 1 -antitrypsin by oxidation of either methionine 351 or 358 provides a mechanism for regulation of its activity at sites of inflammation.
1 is a 52-kDa glycoprotein synthesized mainly by hepatocytes (1) . Its primary function, however, is in the lung parenchyma, where it protects the alveolar matrix from destruction by neutrophil elastase (NE), a serine protease capable of destroying most of the structural components of the alveolar wall (2, 3) . In addition to its presence in the lung, ␣ 1 -AT is abundant in human plasma with concentrations in the 20 -53 M range (4) . When plasma levels of ␣ 1 -AT are below a protective threshold of approximately 11 M, due to mutations of the ␣ 1 -AT gene, the anti-NE protection on the alveolar surface is inadequate, resulting in unopposed proteolytic activity, eventually leading to lung destruction and the development of emphysema by the third or fourth decade of life (5) . These and other data have led to the protease-antiprotease hypothesis to explain the pathogenesis of emphysema (2, 6) .
While there is compelling evidence for this hypothesis in explaining the pathogenesis of emphysema associated with ␣ 1 -AT deficiency, it is less clear why emphysema develops in cigarette smokers with normal levels of ␣ 1 -AT. In this regard, it has been suggested that lung destruction in smokers results from a functional defect in ␣ 1 -AT in the lower respiratory tract secondary to oxidative inactivation (7, 8) . A similar mechanism has been suggested for other oxidant-mediated lung disorders such as hyperoxia-induced lung damage (9) , adult respiratory distress syndrome (10) , cystic fibrosis (11) , and bronchopulmonary dysplasia (12) ; in these diseases, a combination of an increased protease burden and an oxidant-inactivated antiprotease defense exposes the lung to attack.
␣ 1 -Antitrypsin binds to NE in a 1:1 molar ratio with an association constant of 10 7 M Ϫ1 s Ϫ1 (13) . Based on structural similarities with legume protease inhibitors (14) and effects of oxidation of methionine residues, it was proposed that methionine 358 is located at the reactive site of ␣ 1 -AT. For example, oxidation of methionine 358 and possibly other methionines in ␣ 1 -AT to methionine sulfoxide by oxidants (e.g. myeloperoxidase (15) , N-chlorosuccinimide (16) , chloramine-T (17), peroxynitrite (18) , or hydrogen peroxide generated by glycation with glucose and cupric ion (19) ) greatly decreases its activity. Treatment of ␣ 1 -AT with cis-dichlorodiammineplatinum (II) (20) , a square-planar antineoplastic agent, which reacts with DNA and nucleophile side groups of amino acids such as methionine and cysteine, protected methionine 358 against oxidation to its sulfoxide by hydrogen peroxide.
Human ␣ 1 -AT contains nine methionines, and the seminal studies of Johnson and Travis established that two are readily oxidized by chemical and enzymatic systems (16) , methionine 358 and methionine 351. More recent studies of the oxidation of methionine residues in ␣ 2 -macroglobulin and glutamine synthetase led us to hypothesize that readily oxidizable, surfaceexposed methionine residues may function as endogenous antioxidants whose purpose is to protect essential residues from oxidation (21) . We hypothesized that the oxidation of methionine 351 in ␣ 1 -AT was another example, serving to protect the critical methionine 358 from oxidation. To clarify the role of methionine oxidation in ␣ 1 -AT activity, we investigated the site, sequence, and extent of methionine oxidation by hydrogen peroxide, a major oxidizing agent in cigarette smoke (22) , and the effect of oxidation on ␣ 1 -AT inhibition of NE. Contradicting our hypothesis, we found that oxidation of methionine 351 actually causes inactivation of ␣ 1 -AT rather than preventing it.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Purification of Plasma ␣ 1 -AT-The order of oxidation of ␣ 1 -AT methionine residues following oxidative exposure was evaluated using ␣ 1 -AT purified from plasma of an individual with the MM ␣ 1 -AT phenotype. Blood was collected in heparinized tubes on ice. Plasma, isolated by centrifugation, was then applied to an affinity column of anti-␣ 1 -AT polyclonal antibody (DAKO Co., Carpinteria, CA) linked to CNBr-activated Sepharose 4B. ␣ 1 -AT was eluted with a solution of 100 mM sodium carbonate, 500 mM sodium chloride, 5 mM EDTA, and 0.1% NaN 3 at pH 10. The eluate was concentrated by pressure filtration (YM 10) (Amicon) and applied to a Sephadex G-100 gel permeation column. The ␣ 1 -AT peak was collected and applied to an ion exchange column (Mono Q). Purified ␣ 1 -AT from this column was concentrated by pressure filtration (YM-10), and the final ␣ 1 -AT concentration was determined by radial immunodiffusion. The protocol was approved by the NHLBI Institutional Review Board.
Treatment of ␣ 1 -AT with H 2 O 2 -Twenty g of purified human ␣ 1 -AT were incubated for 2 h at room temperature in 1 ml of reaction mixture containing 50 mM potassium phosphate, 100 mM potassium chloride, 1 mM magnesium chloride at pH 5.0 and the indicated concentrations of hydrogen peroxide (30%; Fisher). The concentration of H 2 O 2 was measured at 240 nm (⑀ ϭ 39.
) (23) . At this pH, methionine is oxidized selectively to methionine sulfoxide (24) . At the end of the reaction, a sample was taken to measure anti-NE activity. The activity of ␣ 1 -AT was measured at 410 nm (Beckman DU-70) by titrating increasing amounts of the oxidized sample against a fixed amount of purified human NE (50 nM) of known activity. The proteins were incubated for 30 min, and then residual NE was quantified by assay with the NE-specific substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-nitroanilide (change of absorbance was measured every 20 s for 2 min) (25) . The remainder of the sample was then dialyzed at 4°C, using dialysis cassettes (Pierce), against 5 mM HEPES, 10 mM sodium chloride at pH 7.4, with six changes of buffer, and then dried by vacuum centrifugation (Savant). To measure tryptophan by spectral deconvolution (26) , 350 g of ␣ 1 -AT were used; following reaction, ␣ 1 -AT was dialyzed against 5 mM potassium phosphate, pH 5.0, with six changes of buffer.
CNBr Cleavage and Amino Acid Analysis-CNBr cleaves peptide bonds on the carboxyl side of methionine, yielding homoserine; it does not cleave at methionine sulfoxide (27) . CNBr cleavage was carried out on 20 g of protein dried by vacuum centrifugation (Savant) in 4-ml glass vials (Wheaton) fitted with Teflon-lined caps. CNBr was prepared as a 10 M stock solution in acetonitrile and then diluted to 100 mM with 70% formic acid just before use. One hundred l were added to the vial, which was capped, protected from light by wrapping with aluminum foil, and incubated overnight at room temperature in a hood. These samples were used for peptide sequencing. Amino acid analyses were carried out on 20 g of ␣ 1 -AT with and without CNBr treatment (28) . The model substrate (allatotropin) was incubated at 70°C for 1 h for the CNBr treatment, equivalent to an overnight incubation at room temperature (27) .
Formation of ␣ 1 -AT⅐NE Complexes-Formation of the ␣ 1 -AT⅐NE complexes occurred in a 1-ml reaction mixture containing 38.5 M purified ␣ 1 -AT and 34.5 M NE, 500 mM NaCl, 0.1% Brij, and 100 mM HEPES, pH 7.5, which was incubated at room temperature for 30 min. A sample was taken to quantify for complex formation in 4 -20% SDS-polyacrylamide gradient gels. Ninety-five percent of ␣ 1 -AT migrated as a complex with NE, while 5% of ␣ 1 -AT was cleaved.
Simultaneous Sequencing of Peptide Mixtures-Fractional modification of each methionine residue was quantified in the oxidatively modified proteins. While this might have been accomplished by reverse phase HPLC mapping of proteins cleaved by specific proteases, it is a challenging process complicated by varying recoveries and changing retention times caused by oxidation of the methionine residues. Instead, the technique of simultaneous sequencing of a peptide collection by an automated Edman sequencer was used (21) . This procedure generates quantitative results from which the location and extent of covalent modifications can be determined, provided that the sequence of the protein is known and the cleavage methods are selected to minimize or eliminate ambiguities. The technique has been used to identify the histidine residues modified by metal-catalyzed oxidation of glutamine synthetase, the cysteine residue in carbonic anhydrase modified by glutathiolation, and oxidized methionine residues in glutamine synthetase (21, 29, 30) .
CNBr treatment of ␣ 1 -AT should yield 10 peptides. Sequencing of this collection of peptides will thus generate multiple phenylthiohydantoin-derivatives in each cycle of Edman degradation. The peptide collection and resultant phenylthiohydantoin-derivative patterns will change upon formation of methionine sulfoxide, since CNBr does not cleave these residues. Ambiguities may result from multiple oxidations, but whether this actually occurs can only be determined experimentally for each protein.
The CNBr peptide collection of each of the ␣ 1 -AT preparations was loaded onto the sequencing column of a Hewlett-Packard G1005A automated sequencer equipped with a model 1040 diode array spectrophotometer. Five cycles were run for each protein, providing an overdetermination useful for confirming the status of each methionine.
Peptide Mapping by HPLC-Mass Spectrometry-To provide an independent analytical assessment of the status of Met-351 and Met-358, we prepared a Lys-C digest. ␣ 1 -AT (25-50 g in 50 mM HEPES, 50 mM NaCl, pH 7.0) was dried by vacuum centrifugation in a glass autosampler vial (catalog no. 79909-C, Scientific Resources, Eatontown, NJ). Then 25 l of 200 mM Tris, 2 mM EDTA, pH 8.5, were added followed by 25 l of hexafluoroisopropanol as a denaturant. The sample was again dried and then taken up in 50 l of water. One g of lysyl endopeptidase (catalog no. 125-02543; Wako Chemicals USA, Richmond, VA) was added, and the solution was incubated at 37°C overnight. The peptide mixture was separated by reverse phase HPLC with both spectrophotometric and mass spectrometric detection (model 1100; Hewlett-Packard, Palo Alto, CA) using a Vydac narrow bore C 18 column (catalog no. 218TP5205; Vydac, Hesperia, CA). The initial solvent was 0.05% trifluoroacetic acid with gradient elution by acetonitrile, 0.05% trifluoroacetic acid increasing at 1%/min with a flow rate of 0.2 ml/min. The effluent from the spectrophotometric detector was mixed in a tee with 100 l/min acetic acid pumped by another model 1100 pump, and the mixture was introduced into the mass spectrometer (31) . The capillary voltage was 4500 V, and the fragmentor was programmed to ramp from 50 V at 50 mass units, 80 V at 1500 mass units, and 140 V at 2500 mass units. Data were collected from 550 to 2000 mass units during development of the method and then narrowed to 900 -1300 for routine analyses.
Under the gradient used, the native peptide containing intact Met-351 and Met-358 eluted at ϳ30% acetonitrile, the peptides with either Met-351 or Met-358 oxidized eluted as a doublet at ϳ28% acetonitrile, and the peptide with both methionines oxidized eluted at ϳ26% acetonitrile. The two peaks in the doublet were collected separately, dried, and further digested by dissolving in 50 l of 50 mM Tris, 5 mM CaCl 2 , pH 7.8, and adding 0.2 g of chymotrypsin (catalog no. 1418467; Roche Molecular Biochemicals). The products were analyzed with the same elution program on the HPLC-mass spectrometer. These analyses established that the peptide with oxidized Met-358 eluted first, followed by the peptide with oxidized Met-351. Quantitation of the four peptides of interest was accomplished by integrating the area of the extracted ion chromatogram for each peptide, with a mass/charge ratio of 2 (native ϭ 1130.8, monooxidized ϭ 1138.8, dioxidized ϭ 1146.8). Since the shapes of the peaks were nongaussian, the area of the doublet peak was allocated to the Met-351-and Met-358-oxidized peptides in proportion to their peak heights.
Site-specific Mutants-␣ 1 -AT mutants were produced as recombinant protein in Escherichia coli using the expression vector pFEAT30, containing the ␣ 1 -AT gene with the sequence of the M2 variant and V68L (32, 33) . Mutant ␣ 1 -AT DNA constructs were designed using the QuikChange Mutagenesis kit. Briefly, mutagenic oligonucleotides containing the desired mutation, and each complementary to opposite strands of the plasmid, were extended by polymerase chain reaction using the Pfu DNA polymerase. Following polymerase chain reaction, the parental DNA containing the wild type ␣ 1 -AT cDNA was degraded using the DpnI restriction enzyme. The synthesized DNA containing the desired mutation, which remained intact in the presence of DpnI, was transformed into Escherichia coli XL-1 supercompetent cells. Transformants were obtained and grown in Luria medium with ampicillin. Plasmid DNA was isolated from cultures containing the putative M351V-, M358V-and M351V,M358V-␣ 1 -AT mutations and trans-formed into E. coli BL21(DE3)pLysS cells for expression. Cultures were grown to A 600 of 0.8 and induced with 1 mM isopropyl-thio-␤-D-galactopyranoside for 3 h, the optimal time for maximal ␣ 1 -AT production (34) . Cells were lysed by sonication and spun at 10,000 ϫ g for 20 min. The supernatant was discarded, and the pellet, constituting the inclusion bodies in which ␣ 1 -AT was present, was washed with 20 mM HEPES, pH 7.4. The presence of ␣ 1 -AT in each sample was confirmed by SDS-PAGE and Western blotting (not shown).
The inclusion bodies were solubilized with 6 M guanidine-HCl in 50 mM potassium phosphate, pH 2.5. Solutions were centrifuged at 10,000 ϫ g for 10 min, and the supernatant was retained. ␣ 1 -AT was purified from the supernatant samples by reverse phase HPLC using a Hewlett-Packard diode array-equipped system, model 1050 (Palo Alto, CA). 200-l samples of supernatant were loaded onto a Vydac C 18 column that had been equilibrated with 0.05% trifluoroacetic acid. A gradient was generated using acetonitrile with 0.05% trifluoroacetic acid, ramping rapidly to 40% in 7 min, followed by an increase to 60% over the next 20 min (1%/min). ␣ 1 -AT eluted at approximately 53% acetonitrile.
To refold the protein (34), fractions containing ␣ 1 -AT were dried in a vacuum centrifuge and then dissolved in 8 M urea, 50 mM Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM ␤-mercaptoethanol, and 0.05% Triton X-100. The sample was then diluted 10-fold with 10 mM sodium phosphate, pH 6.5, 1 mM EDTA, 1 mM dithiothreitol. The samples were loaded into dialysis cassettes and dialyzed for 24 h with three changes of buffer. Protein concentration was determined by the Coomassie Blue dye binding method (35) .
RESULTS
Effect of Methionine Oxidation on Activity-As shown by SDS-PAGE (Fig. 1) , treatment with H 2 O 2 did not cleave or cross-link ␣ 1 -AT, NE, or ␣ 1 -AT⅐NE complexes. Methionine sulfoxide content of ␣ 1 -AT following incubation for 2 h at pH 5.0 with increasing concentrations of H 2 O 2 plateaued after three methionines were oxidized ( Fig. 2A) . A similar oxidation in ␣ 2 -macroglobulin has been reported, but a more detailed investigation correlated loss of activity to oxidation of a single tryptophan residue (28) . Therefore, the method of spectral deconvolution was used to quantify aromatic residues in ␣ 1 -AT. No change in tyrosine, phenylalanine, or tryptophan was found (Fig. 2B) . ␣ 1 -AT contains one cysteine, and measurement of that residue, by Ellman's reagent, demonstrated that it was not oxidized by hydrogen peroxide treatment. This was confirmed by SDS-PAGE under nonreducing conditions, in which higher molecular weight aggregates would have appeared if cysteines had been oxidized to cystine (Fig. 1) .
Identification of Oxidizable Methionines in ␣ 1 -AT and an Artifact from Vicinal Methionines-Simultaneous sequencing permitted assessment of the status of each methionine residue following the analysis shown in Table I . As discussed below, methionines 351 and 358 were readily and equally oxidized, while methionine 226 was substantially less sensitive. None of the other six methionines were significantly oxidized by exposure to H 2 O 2 (Fig. 3) . Methionine 221 appeared to be ϳ40% oxidized in the control protein not exposed to H 2 O 2 . If such an oxidation actually occurred in vivo or during in vitro purification, we would expect the residue to be especially sensitive to oxidation by peroxide. However, the apparent 40% oxidation did not increase even following treatment with very high concentrations of H 2 O 2 (Fig. 3) . Methionine 221 forms a vicinal pair with methionine 220. In a recombinant prion protein (36), we have observed a similar apparent partial oxidation of the carboxyl residue of vicinal methionines. 2 Further, the original studies of CNBr cleavage of methionine-containing dipeptides reported yields of about 75% (37) . Each of these observations is consistent with the hypothesis that amino-terminal methionine residues do not react with CNBr as efficiently as methionines at other positions in peptides. Cleavage of methionine 220 by CNBr would release a peptide with methionine 221 at its amino terminus.
To test this possibility, we studied a purified model peptide containing vicinal methionines. Allatotropin is an insect hormone consisting of 13 residues with the sequence Gly-Phe-LysAsn-Val-Glu-Met-Met-Thr-Ala-Arg-Gly-Phe-amide, placing the vicinal methionines at positions 7 and 8. The supplier's claim of Ͼ97% purity was confirmed by reverse phase chromatography and amino acid analysis (not shown). Its mass was confirmed to be that expected by MALDI-TOF mass spectrometry (m/z ϭ 1,487.8; expected ϭ 1,487.8), with no detectable contaminants. Therefore, the model peptide did not contain methionine sulfoxide. Following CNBr treatment, amino acid analysis demonstrated one-third of a residue of methionine sulfoxide. Simultaneous sequencing detected the same amount in cycle 1, indicating that it derived from Met-8, the carboxysited residue of the vicinal methionines. Unlike amino acid analysis and simultaneous sequencing, MALDI-TOF mass spectrometry cannot provide quantitation of yields, but it does provide qualitative identification by virtue of its high mass accuracy. The mass spectrum of the CNBr-treated peptide is shown in Fig. 4 . Three products are expected: 1) residues 1-7 with homoserine at residue 7; 2) homoserine from residue 8, which will not be detected in this analysis; and 3) residues 9 -13. The two expected peptides are present in the spectrum, but two additional peaks are also readily identified. The peak with m/z ϭ 682.0 contains residues 8 -13 with methionine intact (expected m/z ϭ 681.8), and the peak with m/z ϭ 697.9 is the same peptide with the methionine oxidized to methionine sulfoxide (expected m/z ϭ 697.8). These results establish that CNBr does not efficiently react with amino-terminal methionines, leading to the generation of peptides with either methionine or methionine sulfoxide at the amino terminus. Thus, the apparent presence of ϳ40% methionine sulfoxide at position 221 in control ␣ 1 -AT was an artifact.
Oxidation of either Methionine 351 or 358
Inactivates ␣ 1 -AT-Oxidation of methionine 358 has been previously correlated with loss of ␣ 1 -AT activity (16) . As shown in Fig. 3 , methionine 351 is equally susceptible to oxidation, inviting investigation of its possible effect on activity. The percentage of oxidation of either methionine alone could not account for the corresponding loss of ␣ 1 -AT activity; however, a loss of activity caused by oxidation of either residue did account for the observed inactivation (Fig. 5) .
While oxidation of Met-358 is well established to cause inactivation of ␣ 1 -AT, the effect of oxidation of Met-351 has not been reported. Thus, it seemed important to confirm the results obtained by simultaneous sequencing with an independent method of analysis. We therefore developed an HPLC-mass spectrometric method, which quantified the fraction of Met-351 and Met-358 that was oxidized. Analyses of the series of oxidatively modified ␣ 1 -AT confirmed the results obtained with simultaneous sequencing (Fig. 6) . Thus, Met-351 is as susceptible to oxidation as Met-358. Fig. 7 shows that only these two methionines are surface- 
TABLE I
Susceptibility of methionine residues in ␣ 1 -AT to oxidation by hydrogen peroxide and the expected decrease in residue yields during simultaneous peptide sequencing Oxidation of a methionine residue prevents cleavage by CNBr, thus causing a decrease in yield of residues in the following peptide. Assessment of the status of Met-220 and Met-221 can be made in several ways, including examination of the recovery of Arg-223. If both Met-220 and Met-221 are oxidized, then Arg-223 will not appear in cycles 1-5 because it was fused to the peptide beginning at residue 64. If only Met-221 is oxidized, Arg-223 will run in cycle 3 instead of cycle 2. Since there was no change in the recovery of Arg in cycles 2 and 3, Met-220 remained intact. One can also take advantage of the fact that methionine sulfoxide was reduced back to methionine under conditions of Edman sequencing. Thus, yields of methionine during sequencing increased as residues were oxidized. In particular, the yield of Met in cycle 1 was a measure of oxidation of Met-221, and the results agreed with monitoring of Arg-223. The second column refers to oxidation by exposure to hydrogen peroxide. exposed, in agreement with the suggestion that only those methionines on the surface of the molecule are susceptible to oxidation (21, 38) . While the carbon side chain of methionine 226 is reasonably surface-exposed, the sulfur that is the target of oxidation is only partially exposed. The other six methionines are buried. Site-specific Mutants-Four recombinant ␣ 1 -ATs were purified from E. coli: wild-type, M351V, M358V, and M351V/ M358V. The anti-NE specific activities of each were the same and equivalent to that of the plasma ␣ 1 -AT. Each recombinant protein was analyzed by electrospray-mass spectrometry to confirm that site-specific mutations were produced, and all masses were within 2 mass units of theoretical (wild-type, 44,294 (calculated) and 44,295 (observed); M351V, 44,262 (calculated) and 44,264 (observed); M358V, 44,262 (calculated) and 44,264 (observed); and M351V/M358V, 44,230 (calculated) and 44,228 (observed)). From the results described above, we predicted that M351V and M358V would be inactivated by hydrogen peroxide at approximately the same rate, with that rate being distinctly slower than the wild type. The double mutant M351V/M358V should be even more resistant than the single mutants. The time course and concentration dependences shown in Fig. 8 confirm these predictions.
DISCUSSION
Oxidation of either methionine 351 or 358 in ␣ 1 -AT caused loss of anti-NE activity. The partially exposed methionine 226 was less susceptible to oxidation. Although the importance of methionine 358 in the activity of ␣ 1 -AT is very well documented, the role of methionine 351 in ␣ 1 -AT activity is not well defined. Site-specific mutants in which methionine 358 was changed to valine were shown to be relatively resistant to oxidative inactivation by several laboratories (39, 40) . These reports have understandably led to the impression that methionine 351 is not important in the oxidative inactivation of ␣ 1 -AT, but the issue had not been directly investigated. In this   FIG. 4 . MALDI-TOF spectrum of allatotropin cleaved with CNBr. The mass/charge (m/z) of each peak allows identification of the peptide. Peak 1 is the peptide containing the homoserine form of residues 9 -13 (observed 550.6; calculated 550.6). Peak 2 is the intact methionine form of residues 8 -13 (observed 682.0; calculated 681.8). Peak 3 is the methionine sulfoxide form of residues 8 -13 (observed 697.9; calculated 697.8). Peak 4 is the homoserine lactone form of residues 1-8 (observed 777.0; calculated 776.9). regard, Luisetti and Travis (41) have pointed out that available data suggest that oxidation of other methionine residues may be important in the loss of ␣ 1 -AT activity. Our results establish that oxidation of methionine 351 occurs readily in the wild-type ␣ 1 -AT and causes loss of activity under our standard assay conditions. We then postulated that site-specific mutation of methionine 351 would also increase resistance to oxidative modification and that mutation of both methionine 351 and 358 could generate an ␣ 1 -AT even more resistant to oxidative inactivation than the single mutants. These predictions were confirmed with site-specific mutants produced in E. coli.
A recombinant mutant ␣ 1 -AT with only methionine 358 changed to valine was found by previous investigators to be resistant to oxidative inactivation by N-chlorosuccinimide, while the wild type was inactivated (42) . These recombinants were produced in yeast, and the wild-type ␣ 1 -AT was quite labile, requiring mercaptoethanol to restore or prevent loss of activity. This is not the behavior of the human serum ␣ 1 -AT nor recombinant M358V that we have studied. In the human variant, ␣ 1 -AT-Pittsburgh, methionine 358 is changed to arginine, causing a severe bleeding diathesis because the variant ␣ 1 -AT is a potent inhibitor of thrombin, a property not possessed by wild type ␣ 1 -AT (43) . Exposure of ␣ 1 -AT-Pittsburgh to N-chlorosuccinimide did not affect its ability to inhibit thrombin, but this finding may not be relevant to inhibition of elastase by wild type ␣-AT because unoxidized ␣ 1 -AT-Pittsburgh cannot inhibit elastase (44) .
There are several reports that only two methionines are oxidized to methionine sulfoxide when ␣ 1 -AT is exposed to oxidizing agents such as myeloperoxidase/H 2 O 2 (15) or N-chlorosuccinimide (16) . These were identified as methionine 358 and another residue thought to be within six residues. Janoff and Carp (17) confirmed that two methionines were oxidized when ␣ 1 -AT was treated with chloramine T. Maier and colleagues (45) showed that complete loss of activity of ␣ 1 -AT occurred when one methionine was oxidized, as determined by amino acid analysis of the total protein. They assumed that this was methionine 358, but their data are consistent with ϳ50% oxidation of methionines 351 and 358, as shown here.
In contrast to methionines in a number of other proteins (e.g. glutamine synthetase (21)), the other seven methionines in ␣ 1 -AT (63, 220, 221, 226, 242, 374, and 385) do not act as antioxidants or play a protective role in preventing oxidative inactivation of ␣ 1 -AT. In particular, Met-226 was oxidized to a significant extent only after methionines 351 and 358 were oxidized (Fig. 3) . Carp et al. (8) reported that ␣ 1 -AT isolated from bronchoalveolar lavage fluid of smokers contained four residues of methionine sulfoxide with loss of only 40% of antiprotease activity. We observed, however, that a maximum of three methionines were oxidized under relatively harsh conditions, and loss of activity required only oxidation of two residues. Other investigators have also reported the oxidation of two methionines rather than four (15) (16) (17) .
The susceptibility to oxidation of methionines 351 and 358, along with the crystallographic structure of uncleaved ␣ 1 -AT (46, 47) , showing that these methionines are clearly surfaceexposed, suggests strongly that the ␣ 1 -AT molecule is struc- AT (34, 35) . The right view was generated by rotating that on the left by 180°a bout the vertical axis, displaying the "rear view." The carbon atoms of the side chains of the nine methionine residues are colored green and the sulfurs orange. These views were generated by the program Rasmol (53) . The sulfurs of methionine 351 and 358 are completely exposed, that of methionine 226 is only partially exposed, and all others are not visible on the surface of the molecule. tured in such a way as to invite oxidative inactivation. The oxidation is probably an ongoing and necessary part of its in vivo function. This is in clear contrast to the lack of effect on biological activity of oxidation of surface-exposed methionines in at least eight proteins studied to date (21) . Why might it be physiologically favorable for ␣ 1 -AT to have two methionines whose oxidation leads to inactivation? In the lung, ␣ 1 -AT functions mainly as an inhibitor of NE, which is released by neutrophils at sites of inflammation. Luisetti and Travis (41) postulated that a "halo" of oxidizing agents exists around the neutrophil during migration toward its target. During activation, there is an initial burst of oxidation, followed by release of NE. Close to the neutrophil, ␣ 1 -AT would be more efficiently inactivated by oxidation of either methionine 351 or 358 before NE is released (Fig. 9) . Thus, the timing of the oxidative burst assures preservation of elastase activity when it is released. This hypothesis is consistent with the broad substrate specificity of NE and its central role in a number of disease states associated with proteolytic damage in the lung. Irreversible local inactivation of anti-proteases in the lung is potentially deleterious, but human methionine sulfoxide reductase can reduce ␣ 1 -AT and restore its activity (48) . It has been postulated that NE may have other roles, such as modulating protease inhibitor turnover and the acute phase response and facilitating movement of neutrophils through tissue. Thus, after local inactivation of anti-proteases to ease passage of inflammatory cells through tissue, it is possible that anti-protease activity is restored locally to limit further tissue damage. However, when methionine sulfoxide reductase was added to ␣ 1 -AT containing four residues of methionine that had been oxidized with aqueous cigarette smoke and H 2 O 2 , the anti-NE activity of ␣ 1 -AT was not restored (17) . Thus, homeostatic mechanisms involving local inactivation of anti-proteases followed by restoration of anti-protease activity during inflammatory cell migration may involve a fragile balance, easily upset in lung diseases associated with increased protease or oxidant burden.
One such condition is cystic fibrosis, which is characterized in the lung by markedly increased protease levels and increased amounts of oxidants released by inflammatory cells (49) . The anti-protease defenses of the cystic fibrosis lung are inactivated because ␣ 1 -AT and secretory leukocyte protease inhibitor are complexed with or cleaved by NE or modified by oxidants released by inflammatory cells. This leaves active NE on the respiratory epithelial surface, which contributes directly to the lung destruction in cystic fibrosis. Pneumonia and adult respiratory distress syndrome are other disorders in which lung destruction is at least partly due to unopposed action of proteases (10, 50) . In contrast, ␣ 1 -AT deficiency is characterized by a markedly decreased anti-protease capacity and associated lung destruction. Damage is accelerated by cigarette smoke (8) , most likely due to inactivation of residual ␣ 1 -AT or secretory leukocyte protease inhibitor by oxidants in the smoke.
These findings have implications for the pathogenesis and treatment of lung conditions associated with increased protease activity (51) . A number of studies have shown that aerosolized anti-proteases such as ␣ 1 -AT, purified from plasma (49) , and recombinant secretory leukocyte protease inhibitor can inhibit NE in vivo, e.g. in cystic fibrosis (52) . In these conditions, however, very high levels of anti-proteases are required to achieve complete inhibition of NE and restore anti-NE capacity at the respiratory epithelial surface. Since oxidative inactivation is common in an inflammatory milieu, the oxidantresistant anti-protease M351V/M358V could circumvent this problem by maintaining its anti-protease activity, even in an oxidant-rich environment. If local inactivation of ␣ 1 -AT or secretory leukocyte protease inhibitor is required to allow protease-mediated movement of inflammatory cells to their targets, then oxidant-resistant antiproteases could actually impair host defense and tissue repair. FIG. 9 . Proposed mechanism of action of ␣ 1 -AT when activated neutrophils release elastase. In the immediate vicinity of activated neutrophils, the oxidizing species, which are released first, inactivate ␣ 1 -AT. Activity of NE, which is next secreted, is thereby protected. Farther from the neutrophil, where the short lived reactive oxygen species are nonexistent, ␣ 1 -AT can inactivate NE and thereby protect the lung from unrestricted protease action.
